The blue Samurai warrior T cells in the image above are fighting against the red Samurai cancer cells. The blue T cell Samurais on the right have become exhausted and are unable to kill the red Samurai cancers after fighting for a long time. When the blue T cells can take the hot bath using our iPS-T™ technology, they regain the ability to kill all of the red cancers.
your cancer, your cell, your cure
- AMED to Provide Thyas $7.2 Million (JPY 950 Million) Grant for World's First Clinical Trial of iPSC-Derived Killer T Cell Therapy
- Thyas Enters into Joint Research Agreement and Exclusive License for Data and Patents of Clinical Manufacturing of iPSC-Derived CAR-NK Cells
- Dr. Shin Kaneko published a new article in Nature Biomedical Engineering.
- Thyas’ article on “Nature Milestone: T cells" - "Leading the next wave of cancer immune-cell therapies via allogeneic iPS-Ts."
- Thyas opened Shonan office
Your Cell, Your Cure
Thyas wants to save your
Recent immunotherapies have brought hope to cancer patients.
However, they do not work for all the patients.
For your “someone precious”, our mission is to establish personalized cancer immunotherapy using iPSC-derived immune cells.
Be the world’s leader
of iPSC-derived T cell therapy
T cell therapies require a large amount of patient’s lymphocytes as raw material;
it is not easy to produce therapeutic T cells, as T cells in terminal cancer patients are exhausted and weak, and such T cells are hard to expand. Technologies for T cell rejuvenation via iPSC is getting more attention than ever. As a pioneer of iPSC-to-T-cell differentiation technologies, Thyas aims to be the worlds’ leading company of iPSC-derived T cell therapy.
Establish personalized cancer immunotherapy
with both allogeneic and autologous iPS-T
Thyas develops both “off-the-shelf” allogeneic (others) iPS-T and autologous (yours) iPS-T,
to bring the ultimate personalized medicines to all patients suffering from solid tumors;
for those in acute phase we bring timeliness with off-the-shelf products, and for those in stable phase, safety and durable response with autologous products. We believe only the combination of allogeneic and autologous cell therapies can achieve this goal.
Yoshimoto Katsura Ph.D.
Joint-Representative Director, CEO/CTO
Yasumichi Hitoshi M.D. Ph.D., Joined Thyas in 2017. Trained in Immunology, >18 year experience in oncology and metabolism research & development in the US. Being involved in development of T cell therapeutics for clinical testing at Thyas Co. Ltd.. Served as an assistant professor at Kumamoto U. and at Inst. Med. Sci., U. Tokyo, Studied as a Post-Doc at Stanford U. Joined Rigel Pharmaceuticals Inc. and held a position as VP since 2009 to 2016.
Recent advances in medical sciences have delivered novel therapeutics, re-activating and boosting selective cytotoxicity of immune cells against cancers, are demonstrating great potential to cure cancer patients. However, it is still challenging to apply those therapeutics to all patients due to their limited efficacy and indications.
Thyas is developing allogeneic iPS cell-derived T cells (iPS-TTM) for immediate attention, and autologous iPS-TTM for durable responses and cure, to adapt any condition of each cancer patient. iPS-TTM has great potential to cure cancers of unmet needs.
We are working hard to deliver iPS-TTM to all patients as soon as we can. Our first clinical trial is coming up in a few years.
Thank you very much for your continuous support.
Yasumichi Hitoshi MD.PhD.
Joint-Representative Director, COO/CFO
Serves as director at Thyas since 2017, and took office as representative director since Aug. 2020. >25 year experience in investment and corporate/business planning. Worked at Japanese general trading firm as a manager of investment /business development team, promoted global business investments. Specialized in investment in university startups at Kyoto University Innovation Capital Co., Ltd. since 2015. LL.B., Kyoto University. MBA, at Carnegie Mellon University.
The world’s first university biotech was founded in 1976 in the U.S.A. by a venture capitalist and scientists. The success of the company arouse the heated debates on conflict of interest of university researchers, which finally led to the legislation of the Bayh-Dole Act in 1980. Following the path those pioneers paved, 40 years later in Japan, Thyas is run by a scientist and an ex-venture capitalist and striving to achieve its goal. As an ex-university venture capitalist and current representative director of a university startup, I cannot help but feel grateful about the every efforts made by our predecessors to establish the infrastructure of university startups.
It is an exciting challenge to develop the next-gen cancer immunotherapy with iPSC technologies invented in Japan. And the Thyas team are working hard to deliver the therapy to everybody’s “someone precious,” wishing smiles of patients’ and their family’s. Thank you very much.
Scientific Founder, Director
Holds a position as a professor at the Center for iPS cell Research and Application, Kyoto University, and the Faculty of Medicine, University of Tsukuba. An internationally renowned professor and authority on T cell differentiation from iPS cells. Served as the Director and the head of the Facility of iPS Cell Therapy (FiT), Kyoto U. An Expert on Japanese regulations on cell therapy and regenerative therapy products. Received M.D. and Ph.D. at Tsukuba U. (Immunology) and trained as a Post-Doc at San Raffaele Sci. Inst., Italy. Previously served as an assistant professor at Inst. Med. Sci., U. Tokyo, Japan and moved to the present position in 2012.
・A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy. Nat Commun. 2021 Jan 18;12(1):430. doi: 10.1038/s41467-020-20658-3. PMID: 33462228.
・Targeted Disruption of HLA Genes via CRISPR-Cas9
Generates iPSCs with Enhanced Immune Compatibility.
Cell Stem Cell. 2019 Apr 4;24(4):566-578.
・Enhancing T Cell Receptor Stability in Rejuvenated iPSC- Derived
T Cells Improves Their Use in Cancer Immunotherapy.
Cell Stem Cell. 2018 Dec 6;23(6):850-858.e4.
・Generation of rejuvenated antigen-specific T cells
by reprogramming to pluripotency and redifferentiation.
Cell Stem Cell. 2013 Jan 3;12(1):114-26., and many others
Holds a position as the director of the Investment Department at Kyoto University Innovation Capital Co., Ltd. Also serves as a director of Thyas since 2017. Obtained Ph.D. Osaka University. Involved in drug development and target discovery for cancers and urologic diseases at Takeda Pharmaceuticals Co. Ltd., Sumitomo Dainippon Pharma Co Ltd, and Organon Co., Ltd.
Scientific Advisor, Founder
Co-founder of Thyas Co., Ltd. Served as a professor at the Institute of Tuberculosis and Chest Diseases, and the Institute of Regenerative Medicines, Kyoto University, Awarded as a professor emeritus at Kyoto University, Graduated from Department of Physics, the Faculty of Science, Kyoto University, Studied functional diversity of helper T cells and T cell differentiation in thymus, and identified the existence of T cell progenitor and differentiation process of hematopoietic lineage cells. Established the Kyoto T cell conference (KTCC) in 1991, where international interaction among scientists involved in T cell research was promoted. Served as a scientific advisor on immunology and cancer immunotherapy at Thyas Co., Ltd..
・1963: Graduated from Department of Physics, Faculty of Science, Kyoto U.
・1977: Professor at the Institute of Tuberculosis and Chest Diseases, Kyoto U.
・1997: Professor at the Institute of Regenerative Medicines, Kyoto U.
・2002: Guest professor at the Faculty of Medicine, Nippon U. and at Tokyo Medical and Dental University
・2013: CEO, AsTlym Co., Ltd.
・2016: President, Thyas Co., Ltd.
・2017: Scientific advisor, Thyas Co., Ltd.
Support for iPSC-Tcell differentiation technology, preclinical studies, clinical trials and additional indications
Kyoto University Innovation Capital Co., Ltd.
Support for finance, strategic planning and business development
National Cancer Center, Japan
Support for preclinical studies of Thyas’ 1st pipeline
OncoTherapy Science, Inc.
Licensor of the cancer vaccine for Thyas’ 1st pipeline
University of Tsukuba
Exploratory research on new indications
Support for clinical-grade cell production (plan), Collaboration research for My iPS Project
Kyoto Innovation Center for Next Generation Clinical Trials and iPS Cell Therapy (Ki-CONNECT)
Support for IND enabling studies and clinical Trials, Clinical trial location (plan)
University of Toyama
Collaborator for TCR isolation and its selection
R&D Partnership: Close Coordination With Kyoto University and Other Partners
Thyas performs exploratory research, preclinical studies, clinical-grade cell-production, and clinical trials in partnership with Kyoto University and other partners.